Liane Rae Teplitsky Buys 1,024 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky acquired 1,024 shares of the company’s stock in a transaction on Monday, August 31st. The shares were acquired at an average price of $48.80 per share, for a total transaction of $49,971.20. Following the completion of the acquisition, the chief operating officer directly owned 3,094 shares in the company, valued at $150,987.20. The trade was a 49.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Liane Rae Teplitsky also recently made the following trade(s):

• On Tuesday, September 1st, Liane Rae Teplitsky purchased 1,001 shares of Pulse Biosciences stock. The stock was bought at an average price of $49.95 per share, with a total value of $49,999.95.
• On Friday, August 28th, Liane Rae Teplitsky purchased 1,034 shares of Pulse Biosciences stock. The stock was bought at an average cost of $48.35 per share, for a total transaction of $49,993.90.
• On Wednesday, August 26th, Liane Rae Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The shares were bought at an average cost of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Stock Performance

Shares of Pulse Biosciences stock traded up $0.59 during trading on Wednesday, reaching $52.68. The company had a trading volume of 977,767 shares, compared to its average volume of 461,050. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $54.39. The firm’s fifty day moving average is $36.93 and its 200-day moving average is $27.60. The company has a market cap of $3.65 billion, a price-to-earnings ratio of -44.64 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. On average, research analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in Pulse Biosciences by 8.2% during the 1st quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after purchasing an additional 65,884 shares in the last quarter. Deutsche Bank AG bought a new stake in shares of Pulse Biosciences in the 2nd quarter worth $687,000. Panoramic Capital LLC acquired a new stake in shares of Pulse Biosciences in the second quarter valued at $2,719,000. BlackRock Inc. acquired a new stake in shares of Pulse Biosciences in the second quarter valued at $40,672,000. Finally, Formula Growth Ltd. bought a new position in Pulse Biosciences during the second quarter valued at about $832,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on PLSE shares. Canaccord Genuity Group upped their target price on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a report on Monday, August 17th. They issued a “buy” rating and a $58.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.